Overview

Price chart · mood · technical indicators

NSRX

Nasus Pharma Ltd.stock Healthcare

Drug Manufacturers - General

$2.7466.85%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$1.98$10.00

Current: $2.74

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

NSRX

-66.85%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.720.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$32.2MMicro cap

Wall Street coverage

$20.00median target· current $8.25 (+142.4%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 11.63
P/S (TTM): —
EV/EBITDA: —

Profitability & growth

ROE (TTM): 0.0%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: —

Last earnings

Feb 25, 2026 · Estimate $-0.53 · Reported $0.00

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Nasus Pharma Ltd.

Company profile

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company is headquartered in Tel Aviv-Yafo, Israel.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE MKT
Country: USA
Currency: USD

Company profile

HQ: YIGAL ALON 65, TEL AVIV-YAFO, ISRAEL
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$32.2M

Shares outstanding$11.7M

52W high$9.99

52W low$0.00

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

NSRX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Nasus Pharma to Participate in Upcoming Investor Conferences

Two New York investor events will feature Nasus Pharma CFO Eyal Rubin

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma (NSRX) CEO adds 2,900 shares, lifting stake to 156,991

Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)

Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy

Nasus Pharma (NSRX) CEO adds 15,000 shares at $2.04 in buy

Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up?

Nasus Pharma (NSRX) registers resale of 5.39M ordinary shares

Nasus Pharma (NSRX) CFO discloses 126,197 unvested options at $7.56 strike

Nasus Pharma (NSRX) founder reports 1,888,873 direct shares

Nasus Pharma (NSRX) founder discloses share and warrant stakes

Nasus Pharma (NSRX) director discloses 10,000-share option grant details

Nasus Pharma (NSRX) CEO details 318,855 share options in Form 3 filing

[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership

Citizens cuts Nasus Pharma stock price target to $18 on valuation

Nasus Pharma reports Phase 2 results for intranasal epinephrine By Investing.com

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma (NSRX) touts NS002 Phase 2 data and cash runway

About Nasus Pharma Ltd.

Classification

Company profile

NSRX

Market Comparison

NSRX Market Analysis

Overview

NSRX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Nasus Pharma to Participate in Upcoming Investor Conferences

Two New York investor events will feature Nasus Pharma CFO Eyal Rubin

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma (NSRX) CEO adds 2,900 shares, lifting stake to 156,991

Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)

Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy

Nasus Pharma (NSRX) CEO adds 15,000 shares at $2.04 in buy

Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up?

Nasus Pharma (NSRX) registers resale of 5.39M ordinary shares

Nasus Pharma (NSRX) CFO discloses 126,197 unvested options at $7.56 strike

Nasus Pharma (NSRX) founder reports 1,888,873 direct shares

Nasus Pharma (NSRX) founder discloses share and warrant stakes

Nasus Pharma (NSRX) director discloses 10,000-share option grant details

Nasus Pharma (NSRX) CEO details 318,855 share options in Form 3 filing

[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership

Citizens cuts Nasus Pharma stock price target to $18 on valuation

Nasus Pharma reports Phase 2 results for intranasal epinephrine By Investing.com

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma (NSRX) touts NS002 Phase 2 data and cash runway

About Nasus Pharma Ltd.

Classification

Company profile

NSRX

Market Comparison